Sustained Efficacy and Safety of Vardenafil for Treatment of Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Study

Valiquette, Luc; Young, Jay M.; Moncada, Ignacio; Porst, Hartmut; Vézina, Jean-Guy; Stancil, Britt-Nicole; Edmunds, Katharine; Montorsi, Francesco
October 2005
Mayo Clinic Proceedings;Oct2005, Vol. 80 Issue 10, p1291
Academic Journal
OBJECTIVE: To evaluate the reliability, efficacy, and safety of vardenafil, 10 mg, for patients with erectile dysfunction. PATIENTS AND METHODS: Vardenafil-naive patients completed a 4-week treatment-free run-in phase and a 1-week single-dose vardenafil (10 rag) open-label challenge phase. Responders to vardenafil in the challenge phase were randomized to 12 weeks of double-blind, fixed-dose treatment with vardenafil at 10 mg or placebo. Diary responses to Sexual Encounter Profile (SEP) questions about erections and attempts at sexual activity were collected after 4, 8, and 12 weeks of randomized treatment. Adverse events were monitored throughout the study. RESULTS: During the open-label challenge phase, the proportions of patients with a first-time success for penetration (SEP2) and maintenance of erection (SEP3) were 87% and 74%, respectively. Of 600 patients challenged with a single dose of vardenafil at 10 mg, 260 were randomized to vardenafil and 263 to placebo. During the double-blind phase, the reliability of penetration and maintenance rates for patients successful during the challenge phase were significantly greater with vardenafil compared with placebo (83.4% vs 55.8% [SEP2] and 76.6% vs 42.1% [SEP3], respectively). At week 12, patients in the vardenafil group had a consistently higher least squares mean (SE) on the erectile function domain score of the International Index of Erectile Function domain score of the International Index of Erectile Function than patients in the placebo group (23.5 !0.4] vs 15.8 respectively [last observation carried forward]) and a greater proportion of positive responses to the Global Assessment Question (80.8% vs 32.3%, respectively [last observation carried forward]) at each assessment (P<.O01). Vardenafil was generally well tolerated; most adverse events wore mild to moderate, with headache and flushing reported most frequently. CONCLUSION: During this 12-week study, vardenafil produced consistently higher reliability of penetration and maintenance of erection rates compared to placebo and was generally well tolerated in patients with erectile dysfunction.


Related Articles

  • Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.  // Current Medical Literature: Urology;2008, Vol. 14 Issue 3, p73 

    The article discusses research on vardenafil or phosphodiesterase type 5 (PDE5) inhibitor therapy for mild-to-moderate erectile dysfunction. It references a study by J. Zumbé et al, published in the volume 54 issue of "European Urology." The researchers concluded that men with...

  • A pill to treat impotence? Gorman, Christine // Time International (South Pacific Edition);5/20/96, Issue 21, p62 

    Presents information on studies which suggest that a pill called sildenafil, might aid in the treatment of impotency in man. Other treatments available for impotence; Tests conducted on pill; What preliminary results show; Effectiveness of the pill in less than an hour; How drug can aid in the...

  • Vivus' Avanafil Starts Pivotal Testing in Erectile Dysfunction.  // BioWorld Today;12/15/2008, Vol. 19 Issue 242, p2 

    This article reports on the move of Vivus Inc. to start the first of several Phase III trials of the erectile dysfunction (ED) drug avanafil in 2008. The drug is designed for rapid onset of action and has been shown to have a short half-life for reduced side effects. The trial is being conducted...

  • Phosphodiesterase Type 5 Inhibitors: Unmet Needs. Hatzimouratidis, K.; Hatzichristou, D. G. // Current Pharmaceutical Design;10/21/2009, Vol. 15 Issue 30, p3476 

    Erectile dysfunction (ED) has been revolutionized during the last two decades, as several treatment options are available today. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first choice treatment option for ED by most physicians and patients...

  • Topical treatment of erectile dysfunction: Randomised double blind placebo controlled trial... Gomas, Adel; Shalaby, Mohamed // BMJ: British Medical Journal (International Edition);06/15/96, Vol. 312 Issue 7045, p1512 

    Examines the effectiveness of topically applied cream containing three vasodilators in treating impotence. Experience of penile responses; Side effects of treatment; Consideration of topical treatment with the cream before intracavernous injection of vasoactive agents in psychogenic impotence;...

  • The New Sex Pills. McDougall, Christopher; Vigneri, Sarah; Kita, Joe; Russell, Lauren // Men's Health;Sep2003, Vol. 18 Issue 7, p160 

    Provides information on Cialis and Levitra sex pills for impotent men in the U.S. Typical dosage of the drug; Pros and cons; Side effects.

  • Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. Moore, R. A.; Edwards, J. E.; McQuay, H. J. // BMC Urology;2002, Vol. 2, p6 

    Background: Evaluation of company clinical trial reports could provide information for metaanalysis at the commercial introduction of a new technology. Methods: Clinical trial reports of sildenafil for erectile dysfunction from September 1997 were used for meta-analysis of randomised trials (at...

  • GSK and Bayer achieve impressive results in long-term trials of Levitra.  // PharmaWatch: CNS;August 2003, Vol. 2 Issue 8, p26 

    Reports on the result of a clinical trial suggesting the long-term effects of Levitra, a drug jointly developed by Bayer Pharmaceuticals Corp. and GlaxoSmithKline PLC, in treating erectile dysfunction. Percentage of men reporting improvement after taking the drug; Common adverse events...

  • Vision Disorders and Phosphodiesterase Type 5 Inhibitors. Laties, Alan M. // Drug Safety;2009, Vol. 32 Issue 1, p1 

    Phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil, vardenafil and tadalafil) have been in widespread use for the safe and effective treatment of erectile dysfunction (ED) for nearly a decade. During that time, a relatively small number of patients have experienced adverse visual events,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics